A user shared their positive experience with a hair loss treatment regimen including Dutasteride, Minoxidil, RU58841, Nizoral, microneedling, and supplements, reporting no side effects and some hair regrowth. They encouraged others not to fear these treatments, as they are generally safe.
The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.
The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
A person with hair loss since COVID-19 is considering treatments like finasteride and minoxidil but is hesitant due to potential side effects. Suggestions include visiting a dermatologist, using a ketoconazole shampoo, and considering that post-COVID hair loss might be an autoimmune response.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.
The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.
After a hair transplant, the user noticed unexpected new hair growth without using medications or vitamins. Many advised starting treatments like minoxidil and finasteride to maintain the results and prevent future hair loss.
The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
Users are concerned about inconsistencies in the packaging and form of a Minoxidil, finasteride, and Biotin blend from LockLab.co, with some receiving capsules and others tablets. Despite reassurances from customer service about changes due to maintenance, users remain skeptical about the product's authenticity and effectiveness.
RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.